Direct Oral Anticoagulants for Pulmonary Embolism

Area of Science:

• Cardiovascular Medicine
• Hematology
• Pharmacology

Background:

• Venous thromboembolism (VTE) is a significant cardiovascular disease.
• Traditional VTE treatment involves low-molecular-weight heparin and vitamin K antagonists.
• Emerging evidence supports direct oral anticoagulants (DOACs) as effective alternatives.

Purpose of the Study:

• To review the efficacy and safety of DOACs in VTE treatment.
• To highlight the shift in treatment guidelines towards DOACs.
• To explore the expanding role of DOACs in various patient populations and risk strata.

Main Methods:

• Review of clinical trials and post-marketing studies on DOACs for VTE.
• Analysis of guideline changes and recommendations.
• Evaluation of DOAC use in specific patient subgroups and risk categories.

Main Results:

• DOACs demonstrate efficacy comparable to traditional anticoagulants with a better safety profile.
• DOACs are now recommended as first-line therapy for VTE, including pulmonary embolism (PE).
• DOACs are suitable for outpatient management of low-risk PE and for intermediate-to-high-risk PE patients.

Conclusions:

• DOACs represent a significant advancement in VTE management.
• Current guidelines favor DOACs as the initial therapeutic choice for VTE.
• DOACs are safe and effective across diverse patient populations, including those with comorbidities.